Alexandre Brind'Amour1, Claudèle Brault2, Lucas Sidéris3, Lara De Guerke4, Marie-Hélène Auclair4, Pierre Dubé3, Suzanne Fortin4. 1. Division of Surgical Oncology, Maisonneuve-Rosemont Hospital, Montréal, QC. Electronic address: alexandre.brindamour.1@ulaval.ca. 2. Department of Obstetrics & Gynecology, University of Montréal, Montréal, QC. 3. Division of Surgical Oncology, Maisonneuve-Rosemont Hospital, Montréal, QC; Department of Obstetrics & Gynecology, University of Montréal, Montréal, QC. 4. Division of Gynecologic Oncology, Maisonneuve-Rosemont Hospital, Montréal, QC; Department of Obstetrics & Gynecology, University of Montréal, Montréal, QC.
Abstract
BACKGROUND: Endometrial cancer presenting with peritoneal metastases carries a poor prognosis. The addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to the surgical management of these patients has been studied in recent years, but only with cisplatin. CASES: This is a series of 3 patients presenting with endometrial cancer and synchronous peritoneal metastases who underwent cytoreductive surgery and carboplatin HIPEC as primary treatment. Complete cytoreductive surgery was achieved for each patient. No grade 3-5 complications were observed. Two patients died at 12 and 18 months, respectively, and 1 patient was alive with disease at 29 months. CONCLUSION: This case series suggests that the addition of carboplatin HIPEC to the surgical management of peritoneal metastases from endometrial cancer is safe as primary treatment. However, long-term survival remains poor.
BACKGROUND:Endometrial cancer presenting with peritoneal metastases carries a poor prognosis. The addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to the surgical management of these patients has been studied in recent years, but only with cisplatin. CASES: This is a series of 3 patients presenting with endometrial cancer and synchronous peritoneal metastases who underwent cytoreductive surgery and carboplatin HIPEC as primary treatment. Complete cytoreductive surgery was achieved for each patient. No grade 3-5 complications were observed. Two patientsdied at 12 and 18 months, respectively, and 1 patient was alive with disease at 29 months. CONCLUSION: This case series suggests that the addition of carboplatin HIPEC to the surgical management of peritoneal metastases from endometrial cancer is safe as primary treatment. However, long-term survival remains poor.
Authors: Laura M Chambers; Danielle Chau; Meng Yao; Anthony B Costales; Peter G Rose; Chad M Michener; Robert Debernardo; Roberto Vargas Journal: Gynecol Oncol Rep Date: 2021-10-15